|Elimination half-life||48 hours|
|Chemical and physical data|
|Molar mass||282 g·mol−1|
|3D model (JSmol)|
1,4,6-Androstatriene-3,17-dione (ATD) is a potent irreversible aromatase inhibitor that inhibits estrogen biosynthesis by permanently binding and inactivating aromatase in adipose and peripheral tissue. It is used to control estrogen synthesis.
ATD was present in some over-the-counter bodybuilding supplements until 2009 as well as Topical ATD solutions that work transdermally. The product was developed and commercialized in the dietary supplement market place by industry journeyman, Bruce Kneller who holds a United States Patent for use of the compound and related compounds (#7,939,517) and Gaspari Nutrition. ATD has many names in sports supplements including: 1,4,6 etiollochan-dione, 3, 17-keto-etiochol-triene, androst-1,4,6-triene-3,17-dione and many others. These all refer to CAS# 633-35-2.
ATD may cause a positive test for the anabolic steroid boldenone, of which it is a possible metabolite and production contaminant and is also prohibited in amateur and professional sports which forbids aromatase inhibitors.
A related agent is exemestane (Aromasin).
- Covey, DF; Hood, WF (1981). "Enzyme-generated intermediates derived from 4-androstene-3,6,17-trione and 1,4,6-androstatriene-3,17-dione cause a time-dependent decrease in human placental aromatase activity". Endocrinology. 108 (4): 1597–9. doi:10.1210/endo-108-4-1597. PMID 7472286.
- Adkins-Regan, Elizabeth; Cary H Leung (2006). "Sex steroids modulate changes in social and sexual preference during juvenile development in zebra finches". Hormones and Behavior. Elsevier Inc. 50 (5): 772–778. doi:10.1016/j.yhbeh.2006.07.003. PMID 16919276.
- Parr MK, Fusshöller G, Schlörer N, Opfermann G, Piper T, Rodchenkov G, Schänzer W (2009). "Metabolism of androsta-1,4,6-triene-3,17-dione and detection by gas chromatography/mass spectrometry in doping control". Rapid Commun Mass Spectrom. 23 (2): 207–18. doi:10.1002/rcm.3861. PMID 19089863.